Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robotic sutureless and clampless partial nephrectomy.

Central European journal of urology·2026
Same author

External validation of the prostatic inflammation nomogram to predict prostatic inflammation in men with lower urinary tract symptoms.

Minerva urology and nephrology·2026
Same author

Treatment Regret in Patients Undergoing Minimally Invasive Treatments for Benign Prostatic Hyperplasia.

Journal of clinical medicine·2026
Same author

Accuracy, readability, and understandability of European Association of Urology guidelines bot for Sexual and Reproductive Health Guidelines.

The journal of sexual medicine·2026
Same author

Accuracy, readability, and understandability of EAU Guidelines Bot for urinary infections guidelines.

Minerva urology and nephrology·2026
Same author

Optimizing urology residency education in Italy: a national tele-lecture experience.

Minerva urology and nephrology·2026

Related Experiment Video

Updated: Jun 27, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Finasteride for prostatic disease: an updated and comprehensive review.

Cosimo De Nunzio1, Roberto Miano, Alberto Trucchi

  • 1University 'La Sapienza', Department of Urology, Roma, Italy. cosimodenunzio@virgilio.it

Expert Opinion on Drug Metabolism & Toxicology
|December 2, 2008
PubMed
Summary

Finasteride, a 5-alpha-reductase inhibitor, effectively treats benign prostatic hyperplasia and shows chemopreventive properties for prostate cancer. A 5 mg daily oral dose is recommended for these therapeutic benefits.

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Related Experiment Videos

Last Updated: Jun 27, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Area of Science:

  • Urology
  • Endocrinology
  • Oncology

Background:

  • Finasteride is the first potent inhibitor of steroid 5-alpha-reductase.
  • It lowers androgen levels by inhibiting testosterone conversion to dihydrotestosterone.
  • This mechanism offers potential for managing prostate disorders.

Purpose of the Study:

  • To review the clinical applications of finasteride.
  • To highlight its efficacy in benign prostatic hyperplasia (BPH) and prostate cancer prevention.
  • To recommend an optimal dosage for therapeutic use.

Main Methods:

  • Review of randomized and placebo-controlled trials.
  • Analysis of data from the Prostate Cancer Prevention Trial.
  • Clinical practice guidelines for finasteride use.

Main Results:

  • Finasteride improves symptoms and urinary flow in men with BPH.
  • Demonstrated chemopreventive effects against prostate cancer.
  • Oral administration of 5 mg daily is effective.

Conclusions:

  • Finasteride is a valuable therapeutic agent for BPH and prostate cancer chemoprevention.
  • The 5 mg daily dose is recommended for clinical practice.
  • Further discussion is needed regarding its use in high-risk populations for prostate cancer.